|
Parameter
|
Breast cancer (N = 3606)
|
Carboplatin-treated Lung cancer (N = 4497)
|
Cisplatin-treated lung cancer (N = 1154)
|
|---|
| |
OR (95% CI)
|
P value
|
OR (95% CI)
|
P value
|
OR (95% CI)
|
P value
|
|---|
|
age
|
NS
|
NS
|
NS
|
NS
|
NS
|
NS
|
|
CCI
|
1.247 (1.122-1.387)
|
<.0001
|
1.042 (1.012-1.073)
|
0.0052
|
NS
|
NS
|
|
Gender (male as reference)
|
|
Female
|
NA
|
NA
|
0.817 (0.678-0.985)
|
0.0338
|
NS
|
NS
|
|
Days with cyclophosphamide (in breast cancer) or carboplatin or cisplatin (in lung cancer) treatment
|
0.719 (0.619-0.836)
|
<.0001
|
0.942 (0.915-0.969)
|
<.0001
|
NS
|
NS
|
|
Antiemetic regimen (older 5-HT3 RAs as reference)
|
|
Palonosetron
|
0.618 (0.447-0.854)
|
0.0035
|
0.712 (0.586-0.864)
|
0.0006
|
0.707 (0.514-0.972)
|
0.0330
|
- NA: not applicable, NS: Not significant.
